Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Secondary Prevention in Moderate CKD (COLCHIREN)
NCT06998862Phase 3Recruiting
- Sponsor
- Gregorio Marañón University General Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiovascular disease (CVD) and chronic kidney disease (CKD) comparing Colchicine with Placebo (2 arms). Primary endpoint: Cardiovascular events at 3 years. Started Feb 2025; status: recruiting.
02
Drugs
colchicine
03
Conditions
cardiovascular disease (CVD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06998862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998862.